Urinary gamma-glutamyl transpeptidase, an indicator of renal ischaemic injury and homograft rejection
Related Experiment Videos
View abstract on PubMed
Summary
Urinary gamma-glutamyl transpeptidase (GGT) effectively detects kidney damage from ischemia. Elevated GGT levels in canine models and human kidney transplant patients correlate with renal injury and rejection.
Area of Science:
- Nephrology
- Biochemistry
- Transplantation Medicine
Background:
- Gammaglutamyl transpeptidase (GGT) is concentrated in renal proximal tubules, vulnerable to ischemic damage.
- GGT's localization and assay simplicity suggest its utility in assessing renal ischemia.
- Assessing GGT activity offers a potential method for quantifying renal ischemic injury.
Purpose of the Study:
- To evaluate urinary GGT as a biomarker for renal ischemic injury.
- To correlate urinary GGT levels with transplant rejection in human kidney recipients.
Main Methods:
- Canine model of unilateral renal ischemia (90 min and 5 min durations).
- Measurement of urinary GGT activity in experimental animals.
- Daily 24-hour urinary GGT estimations in 20 human kidney transplant patients.
Main Results:
- Canine urinary GGT increased up to 70-fold after 90 min of renal ischemia.
- Significant GGT elevation was observed after only 5 min of ischemia in dogs.
- A strong correlation was found between elevated urinary GGT and clinical diagnosis of transplant rejection in humans.
Conclusions:
- Urinary GGT is a sensitive indicator of acute renal ischemic injury.
- Urinary GGT monitoring can aid in the early diagnosis of kidney transplant rejection.